Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company focused on programmed T cell therapies, has announced its participation in three major upcoming investor conferences in June 2025:
- William Blair 45th Annual Growth Stock Conference on June 3 in Chicago (investor meetings)
- Jefferies Global Healthcare Conference on June 5 in New York (fireside chat with CEO Dr. Christian Itin)
- Goldman Sachs 46th Annual Global Healthcare Conference on June 11 in Miami (fireside chat with CFO Rob Dolski)
Webcasts of the fireside chats will be available on the company's website and archived for 90 days after the presentations.
Autolus Therapeutics (Nasdaq: AUTL), un'azienda biofarmaceutica in fase iniziale di commercializzazione focalizzata sulle terapie con cellule T programmate, ha annunciato la sua partecipazione a tre importanti conferenze per investitori previste per giugno 2025:
- William Blair 45ª Conferenza Annuale sulle Azioni di Crescita il 3 giugno a Chicago (incontri con investitori)
- Jefferies Global Healthcare Conference il 5 giugno a New York (conversazione informale con l'amministratore delegato, Dr. Christian Itin)
- Goldman Sachs 46ª Conferenza Annuale Globale sulla Sanità l'11 giugno a Miami (conversazione informale con il direttore finanziario Rob Dolski)
Le webcasting delle conversazioni informali saranno disponibili sul sito web dell'azienda e archiviate per 90 giorni dopo le presentazioni.
Autolus Therapeutics (Nasdaq: AUTL), una compañía biofarmacéutica en etapa temprana de comercialización centrada en terapias con células T programadas, ha anunciado su participación en tres importantes conferencias para inversores en junio de 2025:
- Conferencia Anual de Acciones de Crecimiento William Blair 45ª el 3 de junio en Chicago (reuniones con inversores)
- Conferencia Global de Salud Jefferies el 5 de junio en Nueva York (charla informal con el CEO Dr. Christian Itin)
- Conferencia Global Anual de Salud Goldman Sachs 46ª el 11 de junio en Miami (charla informal con el CFO Rob Dolski)
Las transmisiones en vivo de las charlas informales estarán disponibles en el sitio web de la compañía y archivadas durante 90 días después de las presentaciones.
Autolus Therapeutics (나스닥: AUTL)는 초기 상업 단계의 생명공학 회사로, 프로그램된 T 세포 치료제에 집중하고 있으며, 2025년 6월에 열리는 세 가지 주요 투자자 컨퍼런스에 참여한다고 발표했습니다:
- 6월 3일 시카고에서 열리는 William Blair 제45회 연례 성장주 컨퍼런스 (투자자 미팅)
- 6월 5일 뉴욕에서 열리는 Jefferies 글로벌 헬스케어 컨퍼런스 (CEO Dr. Christian Itin과의 대화)
- 6월 11일 마이애미에서 열리는 Goldman Sachs 제46회 연례 글로벌 헬스케어 컨퍼런스 (CFO Rob Dolski와의 대화)
대화 세션의 웹캐스트는 회사 웹사이트에서 제공되며, 발표 후 90일간 아카이브됩니다.
Autolus Therapeutics (Nasdaq : AUTL), une société biopharmaceutique en phase commerciale précoce spécialisée dans les thérapies par cellules T programmées, a annoncé sa participation à trois grandes conférences pour investisseurs prévues en juin 2025 :
- 45e conférence annuelle William Blair sur les actions de croissance le 3 juin à Chicago (réunions avec les investisseurs)
- Conférence mondiale de la santé Jefferies le 5 juin à New York (discussion informelle avec le PDG Dr. Christian Itin)
- 46e conférence mondiale annuelle sur la santé Goldman Sachs le 11 juin à Miami (discussion informelle avec le directeur financier Rob Dolski)
Les webdiffusions des discussions informelles seront disponibles sur le site web de la société et archivées pendant 90 jours après les présentations.
Autolus Therapeutics (Nasdaq: AUTL), ein biopharmazeutisches Unternehmen in der frühen kommerziellen Phase, das sich auf programmierte T-Zell-Therapien spezialisiert hat, gab seine Teilnahme an drei bedeutenden Investorenkonferenzen im Juni 2025 bekannt:
- William Blair 45. Jahrestag der Growth Stock Conference am 3. Juni in Chicago (Investorengespräche)
- Jefferies Global Healthcare Conference am 5. Juni in New York (Kamingespräch mit CEO Dr. Christian Itin)
- Goldman Sachs 46. Jahrestag der Global Healthcare Conference am 11. Juni in Miami (Kamingespräch mit CFO Rob Dolski)
Webcasts der Kamingespräche werden auf der Unternehmenswebsite verfügbar sein und 90 Tage nach den Präsentationen archiviert.
- None.
- None.
LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in upcoming investor conferences.
William Blair 45th Annual Growth Stock Conference
Management to host investor meetings
Date: June 3, 2025
Location: Chicago, IL
Jefferies Global Healthcare Conference
Fireside Chat Presentation
Date and time: June 5, 2025; 3:10pm EDT / 20:10pm BST
Location: New York, NY
Presenter: Chief Executive Officer Dr. Christian Itin
Goldman Sachs 46th Annual Global Healthcare Conference
Fireside Chat Presentation
Date and time: June 11, 2025; 1:20pm EDT / 18:20 BST
Location: Miami, FL
Presenter: Chief Financial Officer Rob Dolski
A webcast of the fireside chats will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved and MHRA licensed product, obe-cel, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
Olivia Manser
+44 7780 471 568
o.manser@autolus.com
FAQ
Which investor conferences will Autolus Therapeutics (AUTL) attend in June 2025?
Who will be presenting at Autolus Therapeutics' (AUTL) upcoming investor conferences?
Where can investors watch Autolus Therapeutics' (AUTL) conference presentations?
What type of company is Autolus Therapeutics (AUTL)?
